Health and wellness products company Herbalife (NYSE:HLF) missed Wall Street’s revenue expectations in Q3 CY2024, with sales falling 3.2% year on year to $1.24 billion. Its non-GAAP profit of $0.57 per share was 89.4% above analysts’ consensus estimates.

Is now the time to buy Herbalife? Find out in our full research report.

Company Overview

With the first products sold out of the trunk of the founder’s car, Herbalife (NYSE:HLF) today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals.

Personal Care

While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.

Sales Growth

A company’s long-term performance can indicate its business quality. Any business can put up a good quarter or two, but many enduring ones grow for years.

Herbalife carries some recognizable products but is a mid-sized consumer staples company. Its size could bring disadvantages compared to larger competitors benefiting from better brand awareness and economies of scale.

As you can see below, Herbalife’s revenue declined by 5.3% per year over the last three years as consumers bought less of its products.

This quarter, Herbalife missed Wall Street’s estimates and reported a rather uninspiring 3.2% year-on-year revenue decline, generating $1.24 billion of revenue.

Looking ahead, sell-side analysts expect revenue to grow 3.4% over the next 12 months, an acceleration versus the last three years. Although this projection illustrates the market thinks its newer products will spur better performance, it is still below the sector average.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefitting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Volume Growth

Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful staples business as there’s a ceiling to what consumers will pay for everyday goods; they can always trade down to non-branded products if the branded versions are too expensive.

To analyze whether Herbalife generated its growth (or lack thereof) from changes in price or volume, we can compare its volume growth to its organic revenue growth, which excludes non-fundamental impacts on company financials like mergers and currency fluctuations.

Over the last two years, Herbalife’s average quarterly sales volumes have shrunk by 7.5%. This isn’t ideal for a consumer staples company, where demand is typically stable.

In Herbalife’s Q3 2024, sales volumes dropped 5.4% year on year. This result was a further deceleration from the 5.6% year-on-year decline it posted 12 months ago, showing the business is struggling to push its products.

Key Takeaways from Herbalife’s Q3 Results

We were impressed by how significantly Herbalife blew past analysts’ EBITDA and EPS expectations this quarter. On the other hand, its gross margin and revenue missed Wall Street’s estimates. Overall, we think this was still a decent quarter with some key metrics above expectations. The stock traded up 6% to $7.25 immediately following the results.

Indeed, Herbalife had a rock-solid quarterly earnings result, but is this stock a good investment here? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.